Trial Profile
An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ENSEMBLE
- Sponsors Roche; Roche Farma
- 10 Mar 2024 This trial has been completed in Portugal, according to the European Clinical Trials Database record.
- 13 Oct 2023 Results of an analysis (n=42) from 11 centers assessing early cellular B-cell profiles in patients prior to OCR treatment, while on OCR treatment and after 1 year of therapy discontinuation presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2023 Results reporting the effectiveness, over 4 years, of OCRas a first-line therapy on measures of disability progression in patients with recently diagnosed relapsing-remitting MS , presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis